Hemostasis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented By Product (Laboratory Analyzers, Point-of-Care Testing Systems), Test, End-Use and Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global hemostasis diagnostics market is expected to grow at a CAGR of 8.1% over the forecast period. Rising incidences of blood clotting diagnosis for patients particularly who are more prone to lose excess blood from body during surgeries is the major factors contributing to the growth of the market. According to the National Hemophilia Foundation, in 2019, around 400,000 people were affected by hemophilia. And out of which approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. Hence affecting the growth of the market positively.

Furthermore, increasing awareness about hemostasis conditions is expected to improve the diagnostic rate and preventive care management, which is predicted to substantially increase the testing volume. Advent in technology led to introduction of many novel diagnostic systems and tests such as introduction of automated blood coagulation analyzers, provide significant growth opportunity to this market in coming few years. However, lack of awareness regarding hemostasis disorders in underdeveloped regions and stringent government regulation may restrict the market.

Scope of the Report

Hemostasis diagnostics are those devices which help in the identification of hemostatic defects which leads to excessive bleeding. Hemostasis is a mechanism followed by the body after getting injured, it slows down the blood loss and stop the blood flow. Hemostasis helps in the diagnosis of actual cause of these disorders with history and helps in the treatment. Hemostasis diagnostics market is segmented by product, test, end use and geography.

By Product
Laboratory Analyzers
Automated Systems
Semi-automated Systems
Manual Systems
Point-of-Care Testing Systems
By Test
Activated Partial Thromboplastin Time
D Dimer Test
Fibrinogen Test
Prothrombin Time (PT) Test
By End Use
Diagnostic Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Point-of-Care Testing System Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

The point-of-care testing system segment is predicted to gain the highest share over the forecast period. Continuous developments in R&D activities to miniaturize molecular and professional diagnostic tests is anticipated to drive the demand for the systems. In addition, improvements in lab automation techniques coupled with introduction of cost-effective and high-quality medical solutions is set to propel the growth. Additionally, patients and clinicians are more inclined towards the usage of POC diagnostic tests with increasing levels of patient awareness about the POC processes drives the market growth. Also, minimally skilled professionals efficiently use POC devices for diagnosis, which serves as one of the segmental drivers.

Several private entities such as California Institute of Technology, Dartmouth College and global organizations are also involved in POC development programs. For instance, in August 2018, the American Association for Clinical Chemistry released certification program for POC testing professionals, to improve their diagnostic testing outside the clinical laboratories. Hence the segment is likely to witness lucrative growth over the forecast period.

Hemostasis  market trend

The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America dominates the market with highest market share over the forecast period. The dominance of this region was mainly attributed to the increased healthcare infrastructure, high adoption of advanced automated analyzers, and the presence of large patient pool. In addition, increasing prevalence of numerous blood clot disorders is aggressively propelling the demand for hemostasis diagnosis. According to the National Hemophilia Foundation, in 2019, approximately 20,000 Americans are living with hemophilia, thereby positively impacting the growth of the North America market.

The Asia-Pacific is expected to witness the fastest growth over the forecast period. The developing countries under study are currently undergoing a paradigm shift and are investing huge amount of government funds to procure and install such medical devices into their public healthcare facilities. Growing awareness and presence of a huge patient pool in developing economies such as India and China can further fuel the regional demand.

Hemostasis Diagnostics Market  geo

Competitive Landscape

The major players include companies such Abbott, Sysmex Corporation, Thermo Fisher Scientific, Inc., Instrumentation Laboratory, F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, and Nihon Kohden Corporation. The market is highly competitive due to the presence of large number of market players.

The players are mostly present in the international space, and due to easy global accessibility, they are competing directly to gain bigger share. These are also involved in development of more sophisticated bench top testing products, accounting for significant competition with respect to the distribution network and market presence. For instance, in December 2018, Sysmex Corporation launched its next-generation analyzers in the hemostasis field, the Automated Blood Coagulation Analyzers CN-6000 and CN-3000.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidences of Blood Clotting Disorders

      2. 4.2.2 Technological Advancements for Medical Treatment

      3. 4.2.3 Rising Adoption of Automated Hemostasis Equipment

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness in Developing Countries

      2. 4.3.2 Stringent Government Regulation

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Laboratory Analyzers

        1. Automated Systems

        2. Semi-automated Systems

        3. Manual Systems

      2. 5.1.2 Point-of-Care Testing Systems

    2. 5.2 By Test

      1. 5.2.1 Activated Partial Thromboplastin Time

      2. 5.2.2 D Dimer Test

      3. 5.2.3 Fibrinogen Test

      4. 5.2.4 Prothrombin Time (PT) Test

      5. 5.2.5 Others

    3. 5.3 By End Use

      1. 5.3.1 Hospitals

      2. 5.3.2 Diagnostic Centers

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Abbott

      1. 6.1.1 Beckman Coulter, Inc

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 Grifols, S.A.

      4. 6.1.4 Instrumentation Laboratory


      6. 6.1.6 Sysmex Corporation

      7. 6.1.7 Thermo Fisher Scientific, Inc.


**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hemostasis Diagnostics Market market is studied from 2018 - 2026.

The Hemostasis Diagnostics Market is growing at a CAGR of 8.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Abbott, Sysmex Corporation , Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd , Nihon Kohden Corporation are the major companies operating in Hemostasis Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!